INVENTURUS KNOWLEDGE SO L IKS NIFTY_SMALLNSEPHARMA
Inventurus Knowledge Solutions Limited operates as a technology-enabled healthcare solutions provider. The company offers a care enablement platform that assists physician businesses in outpatient and inpatient care activities in the United States, Canada, and Australia. The company offers a platform that serves healthcare organizations, including health systems/ integrated delivery networks, academic medical centers, multi-specialty medical groups, single-specialty medical groups, ancillary healthcare organizations, and other outpatient healthcare delivery organizations. Inventurus Knowledge Solutions Limited was incorporated in 2006 and is based in Navi Mumbai, India.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Strong return on equity of 31.4%.
- Healthy ROCE of 29.6%.
- Excellent profit margin of 22.6%.
- Compounding revenue at 45.8% over 5 years.
- Profit CAGR of 33.2% over 5 years.
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IKS INVENTURUS KNOWLEDGE SO L NIFTY_SMALLNSEPHARMA | 1,675.60 | 39.68 | ₹28,085.96 Cr | - | 29.57% | 31.44% | 45.76% | 33.21% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,799.20 | 37.59 | ₹4.32 L Cr | 0.92% | 17.94% | 14.72% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 6,667.00 | 68.97 | ₹1.77 L Cr | 0.45% | 18.96% | 16.19% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,410.80 | 68.96 | ₹1.49 L Cr | 0.86% | 9.06% | 16.98% | 13.27% | 20.21% |
| 5 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,401.00 | 29.16 | ₹1.13 L Cr | 0.93% | 14.88% | 11.74% | 7.23% | 11.45% |
| 6 | DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA | 1,303.50 | 25.90 | ₹1.09 L Cr | 0.61% | 14.00% | 11.83% | 10.96% | -2.35% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,077.70 | 21.51 | ₹1.08 L Cr | 0.09% | 19.24% | 18.32% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,267.70 | 19.49 | ₹1.04 L Cr | 0.53% | 28.42% | 26.91% | 19.10% | 131.46% |
| 9 | MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA | 2,375.60 | 51.29 | ₹98,090.71 Cr | 0.08% | 13.78% | 12.45% | 17.73% | 14.28% |
Quarterly Results
Figures in INR.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 657.16 Cr | 723.96 Cr | 740.10 Cr | 814.95 Cr | 857.65 Cr |
| Cost of Revenue | 383.37 Cr | 386.55 Cr | 395.96 Cr | 405.91 Cr | 419.75 Cr |
| Gross Profit | 273.79 Cr | 337.41 Cr | 344.13 Cr | 409.04 Cr | 437.90 Cr |
| Operating Expenses | 120.08 Cr | 139.56 Cr | 134.28 Cr | 159.49 Cr | 171.73 Cr |
| Operating Income | 153.71 Cr | 197.84 Cr | 209.85 Cr | 249.56 Cr | 266.17 Cr |
| EBITDA | 208.45 Cr | 229.44 Cr | 240.86 Cr | 284.76 Cr | 299.69 Cr |
| Interest Expense | 20.54 Cr | 21.02 Cr | 18.08 Cr | 23.34 Cr | 12.68 Cr |
| Pretax Income | 160.16 Cr | 180.09 Cr | 194.88 Cr | 229.37 Cr | 252.96 Cr |
| Tax Provision | 30.48 Cr | 32.28 Cr | 43.34 Cr | 46.04 Cr | 46.99 Cr |
| Net Income | 129.68 Cr | 147.80 Cr | 151.54 Cr | 183.33 Cr | 205.97 Cr |
| Diluted EPS | 7.60 | 8.70 | 8.85 | 10.73 | 12.06 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 1,031.30 Cr | 1,816.91 Cr | 2,663.99 Cr | 3,193.79 Cr |
| Cost of Revenue | - | 509.31 Cr | 974.79 Cr | 1,495.35 Cr | 1,628.67 Cr |
| Gross Profit | - | 521.99 Cr | 842.12 Cr | 1,168.64 Cr | 1,565.11 Cr |
| Operating Expenses | - | 151.37 Cr | 376.05 Cr | 511.59 Cr | 597.92 Cr |
| Operating Income | - | 370.62 Cr | 466.07 Cr | 657.05 Cr | 967.19 Cr |
| EBITDA | - | 389.26 Cr | 559.16 Cr | 808.71 Cr | 1,099.31 Cr |
| Interest Expense | - | 5.36 Cr | 58.94 Cr | 89.77 Cr | 70.25 Cr |
| Pretax Income | - | 359.34 Cr | 441.67 Cr | 606.28 Cr | 904.91 Cr |
| Tax Provision | - | 54.12 Cr | 71.18 Cr | 120.22 Cr | 183.36 Cr |
| Net Income | - | 305.23 Cr | 370.49 Cr | 486.06 Cr | 721.55 Cr |
| Diluted EPS | - | 17.79 | 21.59 | 28.62 | 42.26 |
Compounded Sales Growth
| 5 Years: | 45.76% |
| 1 Year: | 18.50% |
Compounded Profit Growth
| 5 Years: | 33.21% |
| 1 Year: | 38.60% |
Stock Price Performance
| 1 Year: | +11.69% |
| 6 Months: | +6.86% |
| 3 Months: | +8.79% |
| 1 Month: | +7.56% |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 988.31 Cr | 3,027.52 Cr | 3,051.84 Cr | 4,267.88 Cr |
| Current Assets | - | 698.19 Cr | 897.79 Cr | 783.87 Cr | 1,309.64 Cr |
| Cash & Equivalents | - | 123.62 Cr | 143.81 Cr | 180.42 Cr | 388.72 Cr |
| Inventory | - | 0 | 74.70 L | 0 | 5.80 L |
| Receivables | - | 154.96 Cr | 353.94 Cr | 450.03 Cr | 564.48 Cr |
| Total Liabilities | - | 159.67 Cr | 1,869.66 Cr | 1,262.14 Cr | 1,467.64 Cr |
| Current Liabilities | - | 114.94 Cr | 790.02 Cr | 521.18 Cr | 970.05 Cr |
| Long Term Debt | - | 0 | 812.33 Cr | 509.27 Cr | 274.99 Cr |
| Total Debt | - | 52.35 Cr | 1,311.09 Cr | 855.62 Cr | 752.51 Cr |
| Total Equity | - | 828.64 Cr | 1,157.86 Cr | 1,789.69 Cr | 2,800.24 Cr |
| Shares Outstanding | - | 16.67 Cr | 16.67 Cr | 17.16 Cr | 17.16 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 287.98 Cr | 209.77 Cr | 317.89 Cr | 673.59 Cr |
| Investing Cash Flow | - | -155.96 Cr | -1,141.28 Cr | 244.45 Cr | -210.00 Cr |
| Financing Cash Flow | - | -152.19 Cr | 780.37 Cr | -389.49 Cr | -411.80 Cr |
| Capital Expenditure | - | -8.55 Cr | -32.71 Cr | -42.38 Cr | -60.64 Cr |
| Free Cash Flow | - | 279.43 Cr | 177.06 Cr | 275.51 Cr | 612.95 Cr |
| Net Change in Cash | - | -20.17 Cr | -151.14 Cr | 172.85 Cr | 51.78 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 50.6% | 46.3% | 43.9% | 49.0% |
| Operating Margin % | - | 35.9% | 25.7% | 24.7% | 30.3% |
| Net Margin % | - | 29.6% | 20.4% | 18.2% | 22.6% |
| ROE % | - | 36.8% | 32.0% | 27.2% | 25.8% |
| ROCE % | - | 42.4% | 20.8% | 26.0% | 29.3% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IKS